New drug BRY812 targets Hard-to-Treat gynecologic cancers
NCT ID NCT07311538
First seen Jan 09, 2026 · Last updated May 23, 2026 · Updated 23 times
Summary
This study tests a new drug called BRY812 in 56 women with advanced ovarian, endometrial, or ovarian clear cell cancers that have a specific marker (LIV-1). The drug is given by injection to see if it can shrink tumors and how safe it is. The trial is in Phase IIa, meaning it is still early but looking for signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GYNECOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.